Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with β-phenylethyl isothiocyanate and curcumin

被引:115
作者
Kim, JH
Xu, CJ
Keum, YS
Reddy, B
Conney, A
Kong, ANT [1 ]
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Ctr Canc Prevent Res, Piscataway, NJ 08854 USA
[2] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA
[3] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA
关键词
D O I
10.1093/carcin/bgi272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many naturally occurring compounds, including beta-phenylethyl isothiocyanate (PEITC) and curcumin, exhibit significant anti-cancer chemopreventive effects. In this study, we investigated the combined effects of PEITC and curcumin in PC-3 human prostate cancer cells and in PC-3 cells that were stably transfected with an NF-kappa B luciferase plasmid (PC-3 C4). We found an additive effect of PEITC and curcumin for the induction of apoptosis. To elucidate the potential mechanisms of this effect, we studied several critical cellular signaling pathways, including the critical NF-kappa B cell survival signal that is hyper-activated in PC-3 cells and many other cancers. PEITC and curcumin additively inhibited NF-kappa B luciferase activity. Furthermore, the combined treatment significantly increased the activity of poly(ADP-Ribose) polymerase and cleavage of caspase-3 in correlation with apoptotic cell death. Studying upstream signaling events, we found that the phosphorylations of I kappa B alpha and Akt (Ser473, Thr308) were significantly attenuated by the combination of PEITC and curcumin. As these events can be downstream of the activation of epidermal growth factor receptor (EGFR), we pretreated PC-3 cells with PEITC and curcumin and then stimulated them with EGF. EGFR phosphorylations (Y845 and Y1068) were dramatically suppressed by PEITC or curcumin, and more so by the combination. Importantly, the degree of Akt and PI3K phosphorylations induced by EGF were also significantly suppressed. We conclude that the simultaneous targeting of EGFR, Akt and NF-kappa B signaling pathways by PEITC and curcumin could be the molecular targets by which PEITC and curcumin exert their additive inhibitory effects on cell proliferation and ultimately lead to programmed cell death of tumor cells.
引用
收藏
页码:475 / 482
页数:8
相关论文
共 26 条
[1]   NIK is a component of the EGF/heregulin receptor signaling complexes [J].
Chen, DY ;
Xu, LG ;
Chen, L ;
Li, LX ;
Zhai, ZH ;
Shu, HB .
ONCOGENE, 2003, 22 (28) :4348-4355
[2]   Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase [J].
Chen, YR ;
Han, J ;
Kori, R ;
Kong, ANT ;
Tan, TH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39334-39342
[3]  
Chiao JW, 2002, INT J ONCOL, V20, P631
[4]   Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor [J].
Chott, A ;
Sun, Z ;
Morganstern, D ;
Pan, J ;
Li, T ;
Susani, M ;
Mosberger, I ;
Upton, MP ;
Bubley, GJ ;
Balk, SP .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) :1271-1279
[5]   Fruit and vegetable intakes and prostate cancer risk [J].
Cohen, JH ;
Kristal, AR ;
Stanford, JL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (01) :61-68
[6]   Cellular survival: a play in three Akts [J].
Datta, SR ;
Brunet, A ;
Greenberg, ME .
GENES & DEVELOPMENT, 1999, 13 (22) :2905-2927
[7]  
DAVIES P, 1988, AM J CLIN ONCOL-CANC, V11, P1
[8]   Therapeutic potential of curcumin in prostate cancer - IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells [J].
Dorai, T ;
Dutcher, JP ;
Dempster, DW ;
Wiernik, PH .
PROSTATE, 2004, 60 (01) :1-17
[9]  
Dorai T, 2000, MOL UROL, V4, P1
[10]   RETRACTED: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro (Retracted article. See vol. 145, 2019) [J].
Festuccia, C ;
Gravina, GL ;
Angelucci, A ;
Millimaggi, D ;
Muzi, P ;
Vicentini, C ;
Bologna, M .
INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (04) :630-640